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ABSTRACT 
The study was carried out to determine the effects of methanolic extract of Moringa oleifera on 
bacterial isolates from urine of patients with urinary tract infection (UTI).  One hundred and fifty urine samples 
were collected for this study at Ekiti State Teaching Hospital, Ado Ekiti, Nigeria, between March 2015 and June 
2015. Ethical clearance was obtained in order to carry out the study. Microscopical examination of the urine 
smear (wet preparation) revealed presence of yeast (48.0%), bacteria (88.9%), white blood cells (10%) and 
epithelial cells (14%). A total of 89 bacteria were isolated belonging to 40 different bacteria species. The Gram 
positive bacteria isolated include Corynebacterium  accolens, Arthrobacter  mysorens, Rhodococcus  equi, 
Staphylococus aureus, Luteococcus sanguinis, Aerococcus  viridians, Actinomyces urogenitalis, Helicobacillus 
massiliensis, Branchibus cervicis, Arthrobacter cretinolyticus, Streptococcus rubneri among others. While the 
Gram negative bacteria were Cetobacterium somerae, Escherichia coli, Klebisiella  pneumoniae, Yersinia 
frederikseni, Enterobacter aerogenes, Vibrio mimicus, Acinetobacter baumanii, Pantoea agglomerans, Proteus 
mirabilis, Pseudomonas aeruginosa, Citrobacter freundii, Proteus vulgaris among others. The bacteria isolated 
showed multi-drug resistance to the antibiotics tested. None of the bacterial isolates showed susceptibility to all 
the antibiotics tested, as they showed resistance to between 2 to 8 out of the 8 antibiotics tested per organism. All 
the bacteria tested showed evidence of ESBL production, and all of them were susceptible to the methanolic 
extract of dried leaf of Moringa oleifera. The qualitative analysis for phytochemical constituents of the 
methanolic extract of Moringa oleifera indicated the presence of saponnins, flavonoids, steroids and cardiac 
glycosides. The methanolic extract of dried leaf of Moringa oleifera was found to possess potent phytochemicals 
with high inhibitory activities on bacteria of UTIs origin. 
Key words: Antibacterial activity, Moringa oleifera Lam, Methanolic extract, Phytochemicals, Urinary tract 
infections. 
INTRODUCTION 
Human urine can support bacterial growth due to its favourable chemical composition. A urinary tract 
infection (UTI) is an infection that affects part of the urinary tract. When it affects the lower urinary tract it is 
known as a simple cystitis (a bladder infection) and when it affects the upper urinary tract it is known 
as pyelonephritis (a kidney infection). Symptoms of UTI are:  a burning feeling when you urinate; a frequent or 
intense urge to urinate, even though little comes out when you do; pain or pressure in your back or lower abdomen; 
cloudy, dark, bloody, or strange-smelling urine; feeling tired or shaky; as well as fever or chills (Nicolle, 2008).  
Urinary tract infection (UTI) occurs when there is an anatomical or functional break in the host defence system, 
therefore allowing for the adherence, multiplication and persistence of microorganisms in that part of the urinary 
tract (Brook et al., 2010). Urinary tract infection is one of the most important causes of morbidity in the world 
population, affecting all age groups. Anatomically urinary tract is divided into an upper portion composed of 
kidneys, renal pelvis, and urethers and a lower portion made of urinary bladder and urethra (Foxman, 1990). UTI is 
an inflammatory response of the urothelium to bacterial invasion that is usually associated with bacteriuria and 
pyuria. UTI may involve only the lower urinary tract or both the upper and the lower tract. Urinary tract infection 
may be asymptomatic or symptomatic; asymptomatic which is defined as true bacteriuria is the absence of specific 
symptoms of the urinary tract infection while symptomatic is define as bacteriuria with symptoms (McCormick et 
al., 2008). 
Moringa oleifera commonly referred to as Moringa. It is an exceptionally nutritious vegetable tree with a variety 
of potential uses. These leaves have high medicinal value (Fahey, 2005). Various parts of this plant such as the 
leaves, roots, seed, bark, fruit, flowers and immature pods act as cardiac and circulatory stimulants, possess anti 
tumor, antipyretic, antiepileptic, anti inflammatory, antiulcer, antispasmodic, diuretic, antihypertensive, 
cholesterol lowering, antioxidant, antidiabetic, hepatoprotective, antibacterial and antifungal activities, and are 
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being employed for the treatment of different ailments in the traditional system of medicine (Nikkon et al., 
2003). 
 
The aim of this study is to look into the possibility of the future use of Moringa oleifera in treating urinary tract 
infections. The objectives of the study are to: (a) isolate, characterise and identify bacteria that are associated 
with the urinary tract infections, (b) investigate the bacterial isolates’ susceptibility to antibacterial agents, (c) 
determine the phytochemical constituents of Moringa oleifera, and (d) determine the effect of Moringa oleifera 
extracts on microorganisms that are drug resistant. 
 
MATERIALS AND METHODS 
Study area and population 
This study was conducted at the Ekiti State University Teaching Hospital (EKSUTH), Ado-Ekiti Ekiti State, 
Nigeria over a period of three month (March-June, 2015). One hundred and fifty patients with urinary tract 
infections during the study period were randomly recruited. Approval was sought and collected from the 
Research/Ethics Committee of the Ekiti State University Teaching Hospital before the commencement of the 
research work. 
Sampling Techniques 
Sterile universal bottles were used to collect the urine samples from patients in EKSUTH and the samples 
transported from the hospital to the Microbiology laboratory of Afe Babalola University Ado-Ekiti (ABUAD), 
using a cold box, for microbiological investigations. 
Sample processing 
Using a micropipette, 0.1ml of well-mixed un-centrifuged urine was inoculated on plate count agar and Cysteine 
lactose electrolyte deficient (CLED) agar using the pour plate method. The plates were incubated aerobically at 
37 C̊ for 24 hours and counts were expressed in colony forming units per millimetre (CFU/ml). 
Ten (10) ml of each urine sample was centrifuged at 1000g for 5 minutes, the supernatant was discarded and a 
drop of the well mixed sediment was transferred unto a microscope slide and covered with a cover slip. It was 
examined microscopically at high magnification (x100) for the presence of pus cells, red blood cells, epithelial 
cells, casts, crystals and yeast cells. Another drop of the urine sample was transferred to a microscopic slide and 
it was allowed to dry after which it was Gram-stained. It was examine microscopically at high magnification 
(x100) for the presence of bacteria, polymorphonuclear cells e.t.c. 
Inoculation, isolation, characterization and identification of isolates. 
All isolates were characterised using standard microbiological and biochemical tests as described by Barrow and 
Feltham (1993), and Cheesbrough (2006). Bacterial isolates were identified with the help of online Gideon 
informatics (1994-2014), with reference to Barrow and Feltham (1993) and Garrity et al (2005). 
Antibiotic susceptibility test 
All the isolated organisms were tested for antibiotic susceptibility using Kirby-Bauer disc diffusion method on 
Mueller-Hinton agar. This was carried out by making an even spread of the pure isolates on prepared Mueller-
Hinton agar using sterile swab sticks and aseptic placement of the antibiotics discs using sterile forceps. The 
plates were incubated aerobically at 37 ̊ C for 24 hours after which the zones of inhibition were measured and 
interpreted according to Clinical and Laboratory Standards Institute (CLSI, 2013). Antibiotics used were; 
Ceftazidime (CAZ) (30µg),  Cefuroxime (CXM) (30µg), Ceftriazone (CRO) (30µg), Augmentin (AUG) (30µg), 
Ofloxacin (OFL) (5µg), Gentamicin (GEN) (10µg), Nalidixic acid (NAL) (30µg), Nitrofurantoin (NIT) (200µg), 
Amoxycillin (25µg), Tetracycline (25µg) for gram negative isolates and Cefixime (30µg), Cloxacillin (CLO) 
(5µg), Augmentin, (AUG) (30µg), Cotrimoxazole (COT) (25µg), Erythromycin (ERY) (5µg), Gentamicin 
(GEN) (10µg), Streptomycin (STR) (10µg), Tetracycline (TET) (10µg) and Chloramphenicol (CHL) (10µg) for 
gram positive isolates. 
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Assay for ESBL production 
Assay for production of extended spectrum β lactamase production by the bacterial isolates from urine sample 
was determined phenotypically by the double disc method as described by Clinical and Laboratory Standards 
Institute [2013]. Antibiotics used are: Ceftazidine (30µg) and Ceftazidine/Clavulanic acid(30/10µg); Cefuroxime 
(30µg) and Cefurozime/Clavulanic acid(30/10µg); Ceftriazone (30µg) and Cetriaxone/Clavulanic acid 
(30/10µg). ESBL production by an organism was determined by calculating the difference in the diameter of the 
zone of inhibition produced when an antimicrobial agent is used singly and when it is combined with clavulanic 
acid. ESBL production is shown by a difference equal to or greater than 5mm. (eg, ceftazidime zone =16; 
ceftazidime/clavulanic acid zone=21), Clinical and Laboratory Standards Institute [2013]. 
 
Plant sample collection 
The Moringa leaves used in this research work were obtained from ABUAD Moringa plantation, in the teaching 
and research farm of Afe Babalola University Ado-Ekiti (ABUAD), Nigeria. 
Preparation of Moringa (Moringa oleifera extracts) 
The leaves were gotten fresh and air dried for weeks. After drying, the leaves were grinded to fine powder using 
the electric blender. The powdered Moringa (100g) was soaked into 500ml of methanol, left for 72 hours at room 
temperature after which it was filtered using filter paper. The extract was obtained by drying off the methanol 
with the use of rotary evaporator. 
Antimicrobial activity of Moringa extracts using Agar-well diffusion method 
Susceptibility of the isolated organisms to moringa extracts was determined by agar well diffusion technique 
using Mueller-Hinton agar. Seven millimetre (7mm) diameter wells were prepared on agar containing a 
suspension of each isolated organisms. The methanolic extracts were diluted, using DMSO as diluents and 
different concentrations (500-100mg/ml) were added to the wells. The plates were left at ambient temperature 
for 15 minutes and then incubated at 37 ̊ C for 24hours, after which the zones of inhibition were observed and 
recorded. 
Phytochemical analysis 
Tests for the presence of the following plant secondary metabolites: alkaloids, saponins, tannins, flavonoids, 
steroids and cardiac glycosides were carried out on the methanolic extracts of the leaf of Moringa oleifera as 
described by Sofowora (2008). 
Test for alkaloids: A volume 2ml of the extract was added to 1ml of aqueous hydrochloric acid. A few drops of 
saturated picric acid solution were added. A cream coloured precipitate obtained indicated the presence of 
alkaloid. 
Test for tannins: To 2ml of the plant extract was dissolved in 10ml of distilled water and filtered. 2 ml of the 
extract was added to 2ml FeCl3. If a blue-black precipitate was obtained, this indicated the presence of tannins. 
Test for saponins (Frothing test): From the extract, 0.5ml was added to 5ml distilled water. Frothing presence 
indicated presence of, saponnins. 
 Test for flavonoids: About 2ml of plant extract was weighed in a test tube and dissolved diluted NaOH and 
diluted HCl were added. The presence of yellow solution that colourless indicates the presence of flavonoids 
(Sofowora, 2008). 
Test for steroids: A volume of 10ml of plant extract was dissolved in 10ml chloroform and filtered, and 2ml of 
the filtrate was added to 2ml acetic anhydride and Conc H2SO4. Blue-green ring obtained the presence of 
terpenoids. 
Test for Cardiac glycosides: A volume of 2ml of extract was added to 1ml glacial acetic acid, 1ml FeCl3 and 
1ml Concentrated H2SO4. Absence of green-blue colour indicated that cardiac glycosides were absent. 
 
RESULTS 
Urine samples were obtained from 150 Urinary tract infection patients attending Ekiti State University Teaching 
hospital Ado-Ekiti, Ekiti state, aged 30.83±13.39 (16-72) years, and made up of 19 males and 31 females. 
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Microscopical examination of the urine smear (wet preparation) revealed presence of yeast (48.0%), bacteria 
(88.9%), White Blood Cells (10%) and epithelial cells (14%). Macroscopical and microscopical appearances of 
some selected urine samples are presented in Table 1. 
A total of 89 bacteria were isolated belong to 40 different bacteria species. The Gram positive bacteria are; 
Corynebacterium  accolens, Arthrobacter  mysorens, Rhodococcus  equi, Staphylococus aureus, Luteococcus 
sanguinis, Actinomyces urogenitalis, Aerococcus  viridians, Helicobacillus massiliensis, Branchibus cervicis, 
Arthrobacter cretinolyticus, Streptococcus rubneri among others. The Gram negative bacteria are; 
Cetobacterium somerae, Escherichia coli, Klebisiella  pneumoniae, Yersinia frederikseni, Enterobacter 
aerogenes, Vibrio mimicus, Acinetobacter baumanii, Pantoea agglomerans Proteus mirabilis, Proteus vulgaris 
among others (Figure 1).  
The gram positive bacteria isolates were highly susceptible to Ofloxacin (81.81%), but showed varied resistance 
to other antibiotics tested with cloxacillin giving the least susceptibility of 11.36% (Figure 2). The gram negative 
bacteria isolates from urine samples showed varied resistance to all the antibiotics tested, with Augmentin 
(Amoxcillin/clavulate) showing 100% resistance to the isolates (Figure 2). None of the bacterial isolates showed 
susceptibility to all the antibiotics tested, as they showed resistance to between 2 to 8 out of the 8 antibiotics 
tested per organism (Figure 3). 
All the bacterial isolates tested positive for Extended Spectrum Beta Lactamases (ESBL) production. The same 
organisms were susceptible to Imipenem and indication of lack of Carbapenenase production (Tables 2 and 3). 
All the Extended Spectrum Beta Lactamases producing isolates were susceptible to the methanolic extract of 
Moringa oleifera (Tables 4). 
The analysis of the phytochemical components of Moringa oleifera indicated the presence of saponnins, 
flavonoids, steroids and cardiac glycosides, but no alkaloids and tannins. 
DISCUSSION 
Urinary Tract Infection (UTI) is one of the major infections accounting for about 8.3 million visits to doctors 
yearly. This study is designed to investigate the in-vitro susceptibility pattern of bacteria associated with UTI to 
the extract of Moringa oleifera. M. oleifera has been known for its antibacterial and antifungal activities and 
possesses a lot of macro and microelements nutrients (USDA, 2003; Katayon et al., 2005; Kebreab et al., 2005; 
Farooq et al., 2007). 
 
Bacteriological studies were carried out on 150 urine samples and the following bacterial species were isolated 
namely; Cetobacterium somrae, Escherichia coli, Luteococcus sanguinis, Enterobacter aerogenes, Rhodococcus 
equi, Corynebactrium accolens, Staphylococcus pettenkoferi, Staphylococcus aureus, Branchibus cervicis, 
Pantoea agglomerans, Acinetobacter baumanii, proteus spp, Vibrio mimicus, Arthrobacter cretinolyticus, 
Actinomyces urogenitalis, Klebsiella pneumoniae among others. E. coli, Enterobacter aerogenes and 
Cetobacterium somrae were the most common pathogen isolated in patients with UTI in this study. Earlier study 
indicated E. coli as the most common pathogen associated with UTI (Ebie et al., 2001; Njoku et al., 2001). 
Onifade et al. (2005) and Aiyegoro et al. (2007) also reported that E. coli was the most commonly isolated 
pathogen in significant bacteriuria. In a similar study by Nwanze et al. (2007) the most common isolates were 
Escherichia coli (51.2%), S. aureus (27.3%), and Klebsiella pneumoniae (12.8%). This same pattern was also 
reported by Kolawole et al. (2009). 
Several studies have demonstrated that the geographical variability of pathogens occurrence in cases of UTIs is 
limited by the predominance of Gram negative, usually Enterobacteriaceae and particularly E. coli and 
Enterobacter spp., in various regions of the world and the resistance patterns of these organisms can vary 
significantly between hospital, countries and continents (Teppa and Roberts, 2005; Fatima and Ishrat, 2006). 
The bacterial isolates show both resistivity and susceptibility to the antibiotics used. The gram negative bacteria 
were resistant to Augmentin (100%), Cefuroxime (90.91%), Cefixine (59.1%) while they were susceptible to 
Gentamicin (63.63%), Ofloxacin (65.15%) and Nitrofurantoin (77.27%). All the Gram positive bacteria were 
resistant to Ceftazidime (81.82%), Cefuroxime (75%), Erythromycin (77.28%) and Cloxacillin (88.64%) while 
they were susceptible to Ofloxacin (81.81%) and Gentamicin (68.18%).  
This study has demonstrated high antimicrobial potency of methanolic extracts of M. oleifera against urinary 
tract isolates. This tends to correspond with the work of Arun and Purnachandra (2011), who in their work on; 
the phytochemical screening and antibacterial activity of Moringa oleifera against Proteus mirabilis, 
Pseudomonas aeruginosa, Klebsiella pneumoniae and Escherichia coli from urinary tract infected patients 
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Based on the results obtained from this study, various multidrug resistant bacteria belonging to different genera, 
could be associated with Urinary tract infections. It was interesting to observe that methanolic extract of 
Moringa oleifera had antibacterial activities on all the multidrug resistant bacteria tested. A hope for solution to 
the menace in medical treatment caused by multidrug resistant bugs may not be farfetched. Further work should 
be carried out to isolate, purify and possibly characterize the active constituents responsible for the activity of 
this plant. As well as elucidating their possible mechanisms of actions. Traditional use of medicinal plants is 
therefore encouraged. 
 
Table 1: Macroscopy and microscopy analysis of urine samples 
S/N SAMPLE 
CODES 
MACROSCOPY MICROSCOPY (Wet prep) MICROSCOPY (Gram stained) 
1 7 Clear, yellow Bacteria, yeast cells Multiple bacteria 
2 8 Clear, yellow Yeast cells, epithelial Epithelial cells, bacteria(4) 
3 10 Clear, deep amber Yeasts, epithelial Epithelial cells,  bacteria(3) 
4 11 Clear, deep yellow Yeast, WBCs Bacteria (6) 
5 12 Clear, light yellow WBCs, yeast cells Multiple bacteria 
6 13 Turbid, milky  Epithelial cells, crystals Epithelial cells, bacteria (3) 
7 14 Amber, clear Casts, phosphate Polymorphonuclear cells 
8 19 Turbid, yellow Casts, yeast cells Multiple bacteria 
9 20 Milky, turbid Epithelial cells, yeast Multiple bacteria 
10 21 Light yellow, turbid Phospahate, casts Multiple bacteria 
11 22 Golden yellow, turbid Epithelial cells, yeast Bacteria (27) 
12 23 Turbid, yellow Bacteria Multiple bacteria 
13 24 Turbid, yellow Yeast cells Bacteria (6) 
14 25 Turbid, deep amber WBCs, phospahate Bacteria (3) 
15 26 Clear, amber Bacteria Multiple bacteria 
16 27 Clear, white Bacteria Multiple bacteria 
17 28 Clear, white Yeast cells Polymorphonuclear cells 
18 29 Cloudy, amber Epithelial cells, casts Multiple bacteria, epithelial cell 
19 30 Clear, deep amber Epithelial cells, cast Epithelial cells, bacteria (5) 
20 32 Yellow, clear Yeast cells, casts Bacteria (13) 
21 35 Deep amber, turbid WBCs, epithelial Bacteria (5) 
22 36 Clear, yellow Epithelial cells,yeast Multiple bacteria 
23 37 Amber, turbid Casts, yeast cells Bacteria (7) 
24 38 Deep amber, turbid Bacteria, yeast cells Bacteria (12) 
25 42 Amber, clear Yeast cells Epithelial cells 
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FIGURE 1: Frequency of occurrence of bacteria isolated from urine of UTI patients 
 
Figure 2: Antibiotic resistance patterns of bacterial isolates from urine of UTI patients 
 
Figure 3: Multiple drug resistant patterns of bacterial isolated form UTIs 
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Table 2: Extended Spectrum Beta Lactamases production table for Gram positive bacterial isolates 
COD
ES 
 CRO CRO + 
CLAV 
CXM CXM + 
CLAV 
CAZ CAZ + 
CLAV 
IPM 
QUANTITY (µg) 30 30/10 30 30/10 30  30/10 10 
2d Rhodococccus  equi 12a 20a 15b 21b 9 12 32 S 
15a Corynebacterium accolens 9a 16a 13b 18b 7c 14c 27 S 
5c Staphylococcus  pettenkofin 13a 25a 11b 16b 5c 10c 25 S 
23a Rhodococcus  equi 7a 13a 9b 14b 12c 17c 24 S 
4d Staphylococcus aureus 0a 12a 7b 14b 5c 13c 30 S 
2b Rhodococccus  equi 15a 21a 10b 15b 12c 23c 31 S 
4b Rhodococcuss  equi 0a 12a 10 12 17c 25c 36 S 
23c Branchibus cervicis 5a 11a 7b 13b 9c 21c 33 S 
32a Actinomyces  urogenitalis 10 10 7b 13b 5 7 23 S 
23a Rhodococcus  equi 12 17 15 17 13c 18c 34 S 
5b Staphylococcus pettenkoferi 9a 15a 7b 14b 9 10 27 S 
11d Corynebacterium  accolens 8a 16a 7 10 8c 16c 28 S  
17a Corynebacterium accolens 10a 15a 10 10 0c 7c 23 S  
7c Streptococcus rubneri 12a 17a 10b 15b 12c 21c 30 S 
14c Aerococcus  viridians  16a 21a 5b 13b 6 8 26 S 
35b Dietza  maris 10 10 12b 21b 10c 15c 34 S 
 Staphylocccocus aureus 
ATC25923 
9a 14a 14 18 12c 17c 31 S 
abc***Zones of inhibition values within rows with the same superscript indicate Extended Spectrum Beta 
Lactamases production                                                                                                                                                                        
*Values are zones of inhibition in millimetres(mm)                                                                                                            
CAZ  - Ceftazidime,   CXM – Cefuroxime  , CRO – Ceftriazone,  CLAV – Clavulanic acid, IPM  - Imipenem 
Table 3: Extended Spectrum Beta Lactamases production table for Gram negative bacterial isolates 







QUANTITY (µg) 30 30/10 30 30/10 30  30/10 10 
8c Providencia stuartii 0 0 10b 18b 17c 19c 32 S 
31b Cetobacterium somrae 0a 21a 0b 13b 10c 15c 30 S   
33c Klebsiella pneumonia 17 17 10 10 0c 15c 30 S  
23ci Neisseria animaloris 10 12 0b 10b 10 12 23 S 
27e Pantoea agglomerans 9a 21a 0b 8b 20c 25c 32 S 
27d Escherichia coli 17a 26a 10b 18b 6c 15c 32 S 
32c Yersinia frederikseni 15 15 0b 15b 12 13 30 S 
4ai Pseudomonas aeruginosa 16a 26a 5b 13b 6 10 27 S 
11bi Citrobacter freundii 10a 15a 10 10 0c 7c 32 S 
4di Klebsiella pneumonia 7a 17a 9 11 0c 12c 23 S 
10ai Escherichia colii 16a 21a 5b 13b 6 8 34 S 
9ai Proteus vulgaris 16a 27a 8b 17b 6c 12c 25 S 
34e Cetobacterium somrae 7a 17a 10 12 0c 15c 27 S 
7a Cetobacterium somrae 10a 15a 0b 10b 10 12 32 S 
4ai Pseudomonas aeruginosa 9 10 13b 18b 12c 24c 30 S 
40b Vibrio mimcus 9a 16a 13b 18b 7c 14c 31 S 
36d Cetobacterium somerae 17a 21a 9 10 0c 15c 32 S 
Type Proteus mirabilis 
ATCC12453 
9a 19a 13b 18b 7c 14c 28 S 
abc***Zones of inhibition values within rows with the same superscript indicate Extended Spectrum Beta 
Lactamases production                     
    *Values are zones of inhibition in millimetres (mm)      
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          CAZ  - Ceftazidime,   CXM – Cefuroxime  , CRO – Ceftriazone,  CLAV – Clavulanic 
acid IPM  - Imipenem 
 
























*Values are zones of inhibition in millimetres (mm)  
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